Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in t...
Saved in:
Main Authors: | Chen Fu (Author), Lifeng Yu (Author), Yuxi Miao (Author), Xinli Liu (Author), Zhaojin Yu (Author), Minjie Wei (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current status and trends in small nucleic acid drug development: Leading the future
by: Yuxi Miao, et al.
Published: (2024) -
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
by: Chen Fu, et al.
Published: (2024) -
Dental stem cells: Hope or hype?
by: Ashwin Dalal
Published: (2016) -
Blockchain in Health Care: Hope or Hype?
by: El-Gazzar, Rania, et al.
Published: (2020) -
Combination therapy for malaria in Africa: hype or hope?
by: Peter B. Bloland, et al.